Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

iwMPN 2026 | When to switch JAK inhibitor therapy in myelofibrosis

John Mascarenhas, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses the importance of proactively reassessing treatment in patients with myelofibrosis who have an inadequate response to JAK inhibitors. He highlights the need to consider treatment switching when spleen response and symptom control remain suboptimal or anemia and thrombocytopenia develop, rather than waiting until the disease is more advanced. This interview took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, D.C.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

You know, I think probably the biggest one is don’t sit on patients that are not responding well to JAK inhibitors. Unfortunately, you do see that. Like, patients are on maybe ruxolitinib as their first line of therapy, and they’re clearly not optimized on the therapy. They’re on a low dose. Their spleens are still large. They’re still harboring symptom burdens, maybe they’re becoming cytopenic...

You know, I think probably the biggest one is don’t sit on patients that are not responding well to JAK inhibitors. Unfortunately, you do see that. Like, patients are on maybe ruxolitinib as their first line of therapy, and they’re clearly not optimized on the therapy. They’re on a low dose. Their spleens are still large. They’re still harboring symptom burdens, maybe they’re becoming cytopenic. I think often people will wait till sort of the very end to make a treatment switch. And I think it’s very hard to salvage it when the patients are very advanced. So my advice would be if the patient is not optimized, they haven’t had significant spleen response, they still have lingering symptoms, or they’re really developing anemia and thrombocytopenia, to be more on top of that switch. Don’t wait and be reactive. I would say be proactive and think about whether that patient would be better on pacritinib or momelotinib or fedratinib or, you know, I’m always biased, clinical trial.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.